AC Immune (NASDAQ:ACIU) Trading Down 3.7% - Time to Sell?

Key Points

• AC Immune's stock (NASDAQ:ACIU) fell 3.7% to $2.07 on Monday, with trading volume down by 41% compared to its average session.
• Brokerages have mixed opinions; while HC Wainwright cut the target price from $16.00 to $12.00, Wall Street Zen upgraded their rating from "hold" to "buy".
• The company reported a loss of ($0.25) earnings per share, falling short of the consensus estimate of ($0.20), and forecasts a negative EPS of -0.62 for the current fiscal year.

AC Immune (NASDAQ:ACIU - Get Free Report) fell 3.7% during trading on Monday . The company traded as low as $2.07 and last traded at $2.07. 74,122 shares were traded during mid-day trading, a decline of 41% from the average session volume of 124,793 shares. The stock had previously closed at $2.15.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ACIU. HC Wainwright cut their target price on AC Immune from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Wall Street Zen upgraded AC Immune from a "hold" rating to a "buy" rating in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $12.00.

AC Immune Price Performance

The company has a market capitalization of $207.85 million, a price-to-earnings ratio of -3.57 and a beta of 1.65. The stock has a 50 day moving average price of $2.12 and a two-hundred day moving average price of $2.01.

AC Immune (NASDAQ:ACIU - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.05). AC Immune had a negative net margin of 174.94% and a negative return on equity of 49.35%. The business had revenue of $1.65 million during the quarter, compared to analyst estimates of $1.98 million. Sell-side analysts forecast that AC Immune will post -0.62 EPS for the current fiscal year.

Institutional Trading of AC Immune

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sei Investments Co. acquired a new stake in shares of AC Immune in the second quarter valued at $51,000. Acadian Asset Management LLC increased its stake in shares of AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company's stock valued at $679,000 after buying an additional 172,796 shares in the last quarter. BVF Inc. IL increased its stake in shares of AC Immune by 1.5% in the first quarter. BVF Inc. IL now owns 19,822,436 shares of the company's stock valued at $37,068,000 after buying an additional 300,000 shares in the last quarter. Banque Cantonale Vaudoise acquired a new stake in AC Immune in the first quarter worth about $50,000. Finally, Squarepoint Ops LLC acquired a new stake in AC Immune in the fourth quarter worth about $118,000. 51.36% of the stock is currently owned by institutional investors and hedge funds.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.